GLP-1 Insurance Coverage 2026: Medicare, Medicaid, Commercial, Tricare, VA, and FEHB Explained

Insurance coverage for GLP-1 weight loss drugs is the most volatile category in employer pharmacy benefits. The 2025-2026 landscape changed dramatically: the original CMS proposed rule allowing Wegovy under Medicare Part D was rejected in April 2025, then partially reversed by a November 2025 Trump administration deal that created a temporary Medicare GLP-1 Bridge program (July through December 2026) and the BALANCE permanent Medicare model that begins in 2027 [1, 2]. Medicaid coverage shrank from 16 states in October 2025 to 13 in January 2026 after California and Pennsylvania ended their weight-management coverage [3]. Commercial coverage moved the opposite way — 49% of large employers covered GLP-1s in 2025 per the Mercer survey, up from 44% in 2024 [4, 5]. Tricare, the VA, and FEHB all changed their rules. This guide walks through the verified state of coverage across every major US payer category in April 2026.

The Medicare situation: what actually changed in 2025-2026

The Medicare Part D statute (42 USC §1395w-102(e)(2)(A)) prohibits coverage of “drugs used for weight loss.” This rule has applied since the program's inception in 2003 and is the legal foundation for why Medicare beneficiaries historically could not get Wegovy, Zepbound, or any other anti-obesity drug covered through their Part D plan.

Two specific events in 2025 changed (and re-changed) this situation:

1. The November 2024 CMS proposed rule would have removed the weight-loss prohibition under 42 CFR §423.120(b)(1). The Trump administration's final rule (April 8, 2025) did NOT finalize the anti-obesity medication provisions — CMS stated it did not intend to finalize them.
2. The November 6, 2025 Trump administration deal with Novo Nordisk and Eli Lilly created two new pathways [1, 2]:

The Medicare GLP-1 Bridge program (July 1 - December 31, 2026)

Verified details from the CMS Medicare GLP-1 Bridge program page [1]:

• Drugs covered: Foundayo (all formulations), Wegovy (all formulations), Zepbound KwikPen
• Patient cost: $50 copayment per fill
• Eligibility: BMI ≥35 alone, OR BMI ≥27 plus one of the standard weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease)
• Process: Prior authorization required; Humana administers the program on behalf of CMS
• Duration: Temporary — runs through December 31, 2026 only

The BALANCE permanent model (begins 2027)

BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is the CMS Innovation Center model that will replace the Bridge program in 2027 [2]. As of April 2026 the full design details are still in development. CMS has committed to making the model permanent rather than rolling coverage back at the end of the Bridge period.

Ozempic for kidney disease: a separate Medicare path

On January 28, 2025, the FDA approved Ozempic (semaglutide) for reducing the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial (Perkovic et al., NEJM 2024, PMID 38785209). Because this is a diabetes indication and not a weight-loss-only indication, it falls outside the Part D weight-loss prohibition entirely. Medicare Part D covers Ozempic for eligible T2D + CKD patients as a diabetes drug.

Medicaid coverage: a state-by-state patchwork

State Medicaid programs make their own decisions about anti-obesity drug coverage. The KFF January 2026 update [3] reported that only 13 state Medicaid Fee-For-Service programs cover GLP-1s for obesity, down from 16 states in October 2025. The recent retractions:

• California Medi-Cal: ended weight-loss coverage effective January 1, 2026
• Pennsylvania: ended obesity coverage effective January 1, 2026
• North Carolina: eliminated coverage in October 2025, then reinstated in December 2025

The state-level decisions are driven primarily by budget impact — GLP-1 spending hit double-digit percentages of Medicaid pharmacy budgets in many states, and several state legislatures explicitly cited cost as the reason for retraction. A patient on Medicaid should call their state Medicaid office or check the most recent KFF tracker for their specific state, since the situation continues to change quarter to quarter.

Commercial insurance: the Mercer 2025 survey numbers

Commercial coverage moved the opposite direction from Medicaid. The 2025 Mercer National Survey of Employer-Sponsored Health Plans [5] and the 2025 KFF Employer Health Benefits Survey [4] both reported expanded coverage:

• Large employers (≥5,000 workers): 43% covered GLP-1s for weight loss in 2025, up from 28% in 2024
• All large firms: approximately 19% covered for weight loss in 2025
• Mercer overall figure: 49% of large employers covered GLP-1s for weight loss in 2025, up from 44% in 2024
• Cost impact: 59% of employers with coverage reported higher-than-expected utilization, and 66% reported significant impact on their prescription drug spending. Mercer projected a 6.7% health benefit cost increase in 2026 driven in part by GLP-1 spending.

The trend line is for more employers to add coverage but with stricter prior auth criteria — BMI thresholds, documented lifestyle program participation, step therapy through cheaper drugs. See the prior auth section below.

Tricare (military families and retirees)

Tricare made two notable changes in 2025 [6]:

• Active duty + retirees on Tricare Prime/Select: Tricare covers Wegovy and Zepbound with prior authorization. Eligibility: BMI ≥30, or BMI ≥27 with a weight-related condition. Patient must have failed oral anti-obesity medications (Qsymia, Contrave) plus 6 months of documented lifestyle modification. Zepbound PA is valid initially for 6 months, then 12-month renewals.
• Tricare For Life beneficiaries: GLP-1s are NO LONGER covered for Tricare For Life as of August 31, 2025. This is the Medicare-eligible retiree population, so they fall under the Medicare GLP-1 Bridge program instead (with its $50 copayment and BMI ≥35 / BMI ≥27+comorbidity criteria).

Veterans Affairs

VA coverage is split between the diabetes and weight-loss indications [7]:

• For type 2 diabetes: The VA covers Ozempic (and other GLP-1s) for veterans with T2D as part of standard diabetes care.
• For weight loss specifically: The VA covers GLP-1s for veterans with BMI ≥27 plus a weight-related condition (or BMI ≥30 alone) who have failed lower-cost anti-obesity agents and who participate in the VA Whole Health weight management program.
• CHAMPVA (family members): As of January 1, 2025, CHAMPVA covers GLP-1s ONLY for type 2 diabetes diagnosis — not for weight loss alone.

Federal Employees Health Benefits (FEHB)

OPM's 2026 plan year guidance requires that all FEHB plans provide coverage for at least one GLP-1 medication for weight loss plus two oral anti-obesity drugs [8]. Tier placement varies by carrier:

• FEP Blue Focus: Wegovy and Zepbound listed as Tier 2 Preferred (lower copay)
• FEP Blue Basic / Standard: Zepbound listed as Tier 3 non-preferred (higher copay)
• Kaiser FEHB plans: Increased member cost share to 50% for GLP-1s for weight loss in 2026

Prior authorization: what every payer typically requires

Across nearly all payers (commercial, Tricare, VA, FEHB), the standard prior auth criteria for Wegovy or Zepbound for weight management require:

1. BMI threshold: ≥30 alone, OR ≥27 with a documented weight-related comorbidity
2. Comorbidity documentation: ICD-10 code for at least one of: hypertension (I10), type 2 diabetes (E11), dyslipidemia (E78), obstructive sleep apnea (G47.33), or established cardiovascular disease (I25.x)
3. Current vitals: height, weight, and BMI recorded within the past 30 days
4. Lifestyle modification documentation: 6 months of documented diet and exercise records, structured weight loss program participation, or visit notes documenting prior attempts
5. Prior medication trial details: dosage, duration, and reason for failure of any previously tried anti-obesity medication
6. Letter of Medical Necessity from the prescriber

Some payers add specific step therapy requirements. CVS Caremark, for example, requires patients seeking Zepbound to first try Wegovy for 12-16 weeks and demonstrate <5% weight loss or documented intolerance before approving the Zepbound switch. UnitedHealthcare commercial plans vary widely — some require BMI ≥40 for Wegovy approval.

Legislative landscape: TROA and state mandates

The Treat and Reduce Obesity Act (S.1973 / H.R.4231 in the 119th Congress) was reintroduced in 2025 with bipartisan support but has NOT been enacted as of April 2026. TROA would permanently amend the Medicare Part D statute to allow coverage of FDA-approved anti-obesity medications. Its progress is tracked at congress.gov.

At the state level, two states have already passed binding mandates requiring commercial insurance coverage of GLP-1 anti-obesity drugs:

• North Dakota became the first US state in January 2025 to amend its Essential Health Benefits clause to require all individual and group health plans to cover FDA-approved GLP-1 and GIP medications for weight loss as part of ACA compliance.
• California followed with AB 575, effective January 1, 2026, requiring health service plans and insurers to cover at least one FDA-approved GLP-1 receptor agonist with no prior authorization required, and prohibiting coverage criteria more restrictive than the FDA approval label.

At least 14 other states introduced similar legislation in the first half of 2025. The patchwork is tracked by the KFF state legislation database and the Pharmacy Times state mandate tracker.

Self-pay pricing snapshot (April 2026)

For patients without coverage, the manufacturer direct-pay prices as of April 2026 are:

• Wegovy (NovoCare Pharmacy Direct): injectable $199-$499/month depending on dose and introductory status; oral formulation $149-$349/month (the introductory $149 4 mg offer ends August 31, 2026, then reverts to $199/month).
• Zepbound (LillyDirect single-vial): following the December 1, 2025 price reduction: 2.5 mg vial $299/month, 5 mg $399/month, and 7.5/10/12.5/15 mg $449/month with a 45-day refill incentive.
• Foundayo (Lilly oral GLP-1): $25/month with commercial insurance + savings card; $149-$299/month self-pay depending on dose; ~$50/month for eligible Medicare Part D patients via the Bridge program starting July 1, 2026.

For the full cost comparison across all 10 access paths (commercial + direct-pay + compounded + Foundayo), see our GLP-1 savings calculator.

How to find out what your specific plan covers

The fastest way to know what you're actually eligible for:

1. Look up your plan's formulary. Every insurance plan publishes a drug formulary listing covered medications and their tier placement. Search for “Wegovy” or “Zepbound” by name. If the drug is listed, the formulary will note the prior auth requirement and the tier copay.
2. Call the member services number on your insurance card. Ask specifically: “Is Wegovy or Zepbound on my formulary for chronic weight management? What are the prior auth criteria? What would my copay be at tier X?”
3. Check our insurance employer checker if you work for one of the 30 large employers we track. It shows reported coverage status for each.
4. Talk to your prescriber. Many prescribers have benefits navigators or PA specialists who can submit the prior auth on your behalf.
5. Use a manufacturer savings card if eligible. With commercial insurance and an approved PA, the Wegovy and Zepbound savings cards typically bring patient cost to ~$25/month. Foundayo is at $25/month with insurance and $149/month self-pay.

Important disclaimer

This article is educational and reflects the publicly available state of coverage as of April 2026. Insurance coverage decisions change frequently and the specific terms of your plan may differ from the general categories described here. Always verify coverage with your specific insurance plan's member services line and your prescriber before making decisions about your therapy. Weight Loss Rankings does not provide medical or financial advice.

Related research and tools

For employer-by-employer coverage data on 30 large US employers, see our insurance employer checker. For the cost comparison if you do end up self-paying, see our savings calculator. For the new Foundayo $149/month launch that's reshaping the cost floor, see our Foundayo FDA approval deep-dive. For the FLOW kidney trial that opened Ozempic Medicare coverage for T2D + CKD patients, see our FLOW trial deep-dive.